<DOC>
	<DOCNO>NCT02556723</DOCNO>
	<brief_summary>Diabetic macular edema ( DME ) , wet-AMD macular edema secondary vein occlusion lead cause blindness develop country . Several therapy study laser treatment intravitreal injection corticosteroid anti-VEGF drug . In term public health long term treatment current available drug expensive new therapy well effect investigate . This study intend evaluate efficacy safety intravitreal injection ziv-aflibercept treatment patient DME , wet-AMD macular edema secondary vein occlusion .</brief_summary>
	<brief_title>Intravitreal Injections Ziv-aflibercept Macular Diseases</brief_title>
	<detailed_description>Twenty consecutive patient DME , wet-AMD macular edema secondary vein occlusion enrol . A complete examination include full-field ERG , visual acuity , central retinal thickness ( CRT ) evaluation systemic ocular complication perform 24 week intravitreal injection ziv-aflibercept . The twenty patient submit 6 consecutive intravitreal injection ziv-aflibercept 4 week interval . The safety efficacy Eylea treatment macular edema follow CRVO assess 2 randomize , multicenter , double- mask , sham-controlled study : COPERNICUS GALILEO . A total 358 patient treat evaluable efficacy ( 217 Eylea ) two study . In , patient randomly assign 3:2 ratio either 2 mg Eylea administer every 4 week , sham injection ( control group ) administer every 4 week total 6 injection . After 6 monthly injection , patient continue receive Eylea treatment week 24 52 meet pre-specified retreatment criterion ( PRN ) , except patient sham control group GALILEO study continue receive sham injection week 52 . In COPERNICUS study , 6 month , 56 % patient receive Eylea 2 mg monthly gain least 15 letter BCVA baseline , measure ETDRS , compare 12 % patient receive sham injection ( p &lt; 0.01 ) , primary endpoint study . Patients receive Eylea 2 mg monthly gain , average , 17.3 letter vision compare mean loss 4.0 letter sham control injection ( p &lt; 0.01 ) , secondary endpoint . Ziv-aflibercept zaltrap6 ( Sanofi-Aventis US , LLC , Bridgewater , NJ/Regeneron Pharmaceuticals , Inc , Tarrytown , NY ) FDA approve treatment metastatic colorectal cancer . During Bascom Palmer Eye Institute 's Angiogenesis , Exudation , Degeneration February 2014 conference , Michel Eid Farah , João R. Dias , Fernando M. Penha , Eduardo B. Rodrigues investigate safety ziv-aflibercept vitro vivo . In vitro toxicity verify use ARPE-19 culture cell expose anti-angiogenic v balance salt solution ( BSS ) 10 minute . Viability assess 3- ( 4,5-dimethylthiazol-2-yl ) -2,5-diphenyltetrazolium bromide ( MTT ) assay , evaluate cell viability mitochondrial activity . No sign cell toxicity observe , cell viability similar ziv-aflibercept , aflibercept , BSS . For vivo study , test 1 injection 0.05 mL ziv-aflibercept v aflibercept right eye 18 rabbit , 9 eye group . BSS inject fellow eye serve control . After injection , animal examine funduscopy , SD-OCT ) , ERG baseline , 24 hour , 7 day . Aqueous , vitreous , serum sample collect baseline , 24 hour , 7 day pH osmolarity analysis . The animal sacrifice eye enucleate morphologic study light electron microscopy . No abnormality find 24 hour 7 day intravitreal injection either drug assess fundus exam SD-OCT , ERG , histology well transmission microscopy . There also change osmolarity aqueous humor vitreous sample group 24 hour 1 week .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>Adults ≥ 18 year type 1 2 diabetes mellitus BCVA vary 20/62 20/400 ( Snellen chart ) equivalent 0.49 1.30 logMAR cause DME Central Retinal Thickness OCT ( Heildelberg Engineering , Heidelberg , Germany ) 275 mm Laser photocoagulation within previous 6 month Previous intraocular antiVEGF corticosteroid injection Previous systemic antiVEGF receptor tyrosine kinase inhibitor therapy Vitreomacular traction epiretinal membrane produce traction macula SDOCT scan Angiographic evidence macular ischemia define foveal avascular zone great linear dimension 1000 mm severe perifoveal capillary loss Previous cataract , trabeculectomy vitrectomy Aphakia External ocular infection Glaucoma ( IOP &gt; 21 mmHg regular use 2 IOP lower drug ) Likelihood need intraocular surgery within 6 month Proliferative diabetic retinopathy evidence retinal traction Systemic condition preclude trial enrollment include glycosylated hemoglobin 10.0 % Past medical history chronic renal failure require either dialysis kidney transplantation Blood pressure 160/90 mmHg arteriothrombotic event within 6 month randomization , include myocardial infarction , acute congestive heart failure cardiac event , stroke transient ischemic attack Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>